Full Text View
Tabular View
No Study Results Posted
Related Studies
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
This study has been completed.
Study NCT00080015   Information provided by Ipsen
First Received: March 19, 2004   Last Updated: July 23, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Small Cell Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Small Cell
Lung Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Carcinoma, Neuroendocrine
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Diflomotecan (BN80915)
Sponsors listed in this trial
Ipsen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services